eHEALTH BureauClose on the heels of announcing its foray in the orthopaedic segment, Lupin Limited, has announced the availability of Hyalgan, a therapy against degenerative joint disease-osteoarthritis, in India. Hyalgan is a type of intra-articular knee injection that delays the onset and progression of osteoarthritis in patients. It represents a painless, unique and qualitative therapeutic approach in the treatment of osteoarthritis available at affordable prices within the country.Given the rising incidence of osteoarthritis in India, it is an effective option to the growing younger patient population that are increasingly becoming victims of the disease. The remarkable 5-injection therapy works wonders and gives long-lasting relief to patient’s upto a year for every course that is taken, thereby helping patients to get their mobility and freedom back.Dr Vaibhav Kasodekar, a leading Joint Replacement and Arthroscopy surgeon, averred, “Hyalgan is useful even for people who are on other forms of treatment such as painkillers or physical therapy and offers recourse to knee replacement surgery, if detected at an early stage. In acute cases, it can precede a surgical procedure to reduce the severity of the ailment and effectively manage the ailment.”Commenting on the development, Shakti Chakraborty, Group President, India Region Formulations, Lupin, said, “We have successfully test marketed Hyalgan over the last six months with leading doctors in India and are delighted with the initial response. The therapy has been well-received and Hyalgan is available in the form of an injectable across the country. Hyalgan would be accessible via special patient care programs to provide value to the large pool of osteoarthritis patients in the country today.”R D Bhatt, Senior Vice President, Sales and Marketing, Endeavour Division, Lupin, added, “With the rising incidence of osteoarthritis in recent times, patients in the age bracket of 35-40 years are increasingly getting associated with the disease, which was earlier observed in patients in the age group of 55-65 years.”

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.